Allerfen - 60 mg 30 Tablets

A drug for the elimination of symptoms associated with seasonal allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.

Tradename: Allerfen

Composition: Each film-coated tablet contains 180 mg of fexofenadine hydrochloride.

Auxiliary components: lactose, microcrystalline cellulose, colloidal silicon dioxide, povidonec30, crospovidone, talc, magnesium stearate, pink opadrium.

Pharmacological group: antiallergic agent, blocker of HI-histamine receptors.

Pharmacological properties: Fexofenadine is the active metabolite of terfenadine. After a single or 2-fold administration, the drug exhibits an antihistamine effect, starting from 1 hour, reaching a maximum effect after 6 hours and continuing for 24 hours. Has no sedative effect. There was no evidence of habituation to these effects after 28 days of dosing.

Indications: Elimination of symptoms associated with seasonal allergic rhinitis and uncomplicated cutaneous manifestations of chronic idiopathic urticaria.

Dosage and administration: for adults and children aged 12 years and older, the recommended dose is 180 mg 1 time per day before meals.

Children under the age of 12. The effectiveness and efficiency of using fexofenadine hydrochloride in children under 12 years of age have not been studied.

Studies in special risk groups (elderly patients, with renal and hepatic insufficiency) have shown that for patients of these categories, no dose adjustment is required.

Warnings and precautions: As with most new drugs, data on the elderly and patients with impaired renal function or hepatitis are limited, and caution should be exercised when prescribing fexofenadine hydrochloride in these special groups. Patient groups with a history of or ongoing cardiovascular disease should be warned t antihistamines can cause side effects such as tachycardia and palpitations.

Side effects: Fexofenadine is generally well tolerated. The most frequently (1-10% of cases) reported headache, fatigue, dizziness or drowsiness, and nausea. In placebo-controlled studies with a frequency of less than 1%, weakness, insomnia, nervousness, sleep disturbance, tachycardia, palpitations, diarrhea were noted. In rare cases (less than 0.1%), exanthema, urticaria, itching, Quincke’s edema, difficulty breathing, shortness of breath, skin redness, anaphylactic reactions were observed.

Drug interaction: concomitant use with ketoconazole and erythromycin may cause an increase in plasma concentration of fexofenadine. An antacid containing aluminum and magnesium can reduce the absorption of fexofenadine, the recommended interval between doses of these substances should be at least 2 hours.

Pregnancy Category B:

There are no adequate and well-controlled studies in pregnant women. Fexofenadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: there are no data on the content of fexofenadine in breast milk when it is taken by breastfeeding women. Its penetration into breast milk was observed. The use of fexofenadine during breastfeeding is not recommended.

Impact on the ability to drive:

In objective tests, it was shown that fexofenadine does not significantly affect the function of the central nervous system. This means that patients can drive a car or perform tasks that require concentration. However, in order to identify sensitive individuals who have unusual drug reactions, it is advisable to test individual reactions before performing challenging tasks.

Storage: Store at a temperature not exceeding 30 C dry place out of the reach of children.

Package: Carton box holds 1,2 or 3 strips of 10 film coated tablets.